Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus cisplatin concurrent radiotherapy for cervical cancer
ChiCTR1800016391Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Objective response rate and Disease control rate. Started Jan 2018; status: recruiting.
02
Drugs
Rivoceranibcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800016391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016391.